<DOC>
	<DOCNO>NCT00244764</DOCNO>
	<brief_summary>Phase II , multi-center , two-stage study utilise randomised discontinuation design evaluate safety efficacy GW786034 ( pazopanib ) adult subject locally recurrent metastatic clear-cell Renal Cell Carcinoma ( RCC ) . After interim analysis , design change open label , single arm study subject receive pazopanib .</brief_summary>
	<brief_title>GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis Renal Cell Carcinoma predominantly clearcell histology ( exclude chromophobe , papillary , collect duct , undifferentiated tumor ) metastatic locally recurrent Either prior systemic therapy fail 1 prior cytokinebased bevacizumabbased therapy Evidence document measurable disease RECIST criterion Male female least 21 year age A woman eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is postmenopausal ( total cessation menses &gt; = 1 year ) . 2 . Childbearing potential , negative serum pregnancy test Screening Period serum urine pregnancy test Day1 , agree use adequate contraception . GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device ( IUD ) document failure rate le 1 % per year . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigation product , clinical trial , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . A man female partner childbearing potential eligible enter participate study use barrier method contraception ( e.g . condom ) abstinence study 28 day follow last dose investigational drug . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Adequate bone marrow function . Adequate hepatic function . Adequate renal function . Adequate PT/PTT INR/aPTT . Able swallow retain oral medication . Written informed consent . Exclusion criterion : Received prior noncytokine nonbevacizumab therapy . Received chemotherapy renal cell carcinoma . Have major surgery , radiotherapy , immunotherapy within last 28 day and/or recover prior therapy . History hypercalcemia within two month start therapy . Patients pregnant lactate . Poorly control hypertension . QTc prolongation define QTc interval ≥ 480 msec significant ECG abnormality . Has Class II , III IV heart failure define New York Heart Association functional classification system . A subject history Class II heart failure asymptomatic treatment may consider eligible . Any history cerebrovascular accident [ CVA ] . History myocardial infarction , admission unstable angina , cardiac angioplasty stenting within last 12 week . History venous thrombosis last 12 week . Current use therapeutic warfarin . Use antiplatelet agent aspirin ( ≤ 325 mg/day ) . Leptomeningeal brain metastasis . Prior history malignancy renal cell carcinoma ( except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast , subject free malignancy &gt; 5 year ) . Any serious and/or unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism excretion study drug . Has unresolved bowel obstruction diarrhea . Psychological , familial , sociological , geographical condition permit compliance protocol . Is specifically prohibit medication require medication treatment GW786034 .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Pazopanib ( GW786034 )</keyword>
</DOC>